The preplanned second interim OS did not reach statistical significance, requiring longer follow-up to fully assess the OS benefit.
← all excerpts
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.
1
—
—